← Back to patent-cliff list
SIR9900
Tier C — Watch / tradeSIR9900
Sironax Aus Pty Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：RIPK1
Indications (approved)：VEXAS综合征, 全身炎症反应综合征
Regional status
US
-
EU
-
China
Phase II
2026-05-28
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of SIR9900?
Approved indications include: VEXAS综合征, 全身炎症反应综合征.
When does the SIR9900 patent expire?
No public expiry year is available for SIR9900 yet; this page updates once verified.
How do I get a quote for SIR9900 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29